DSC Advisors, L.P. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 171 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.

Quarter-by-quarter ownership
DSC Advisors, L.P. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2018$1,008,000
-20.3%
10,0000.0%0.12%
-28.2%
Q3 2018$1,264,000
+50.7%
10,0000.0%0.17%
+24.1%
Q2 2018$839,000
+290.2%
10,000
+185.7%
0.14%
+204.4%
Q1 2018$215,000
+5.4%
3,5000.0%0.04%
-61.9%
Q4 2017$204,000
-77.3%
3,500
-50.0%
0.12%
-77.9%
Q1 2016$899,000
-14.0%
7,0000.0%0.53%
-2.2%
Q4 2015$1,045,000
-10.0%
7,0000.0%0.55%
-3.2%
Q3 2015$1,161,000
-31.3%
7,0000.0%0.56%
-35.8%
Q2 2015$1,690,000
-14.4%
7,0000.0%0.88%
-16.1%
Q1 2015$1,974,000
-9.6%
7,000
-50.0%
1.05%
+65.6%
Q4 2014$2,184,00014,0000.63%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2017
NameSharesValueWeighting ↓
Carmignac Gestion 2,028,192$229,389,0001.76%
Orbimed Advisors 1,037,000$117,285,0001.33%
BB BIOTECH AG 255,719$28,922,0000.95%
ALTRINSIC GLOBAL ADVISORS LLC 193,369$21,870,0000.74%
FALCON POINT CAPITAL, LLC 44,573$5,041,0000.67%
Rhenman & Partners Asset Management AB 30,000$3,393,0000.54%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 11,155$1,262,0000.48%
NATIONAL PLANNING CORP 52,400$5,888,0000.44%
HIGHFIELDS CAPITAL MANAGEMENT LP 364,232$41,195,0000.38%
SPHERA FUNDS MANAGEMENT LTD. 15,000$1,697,0000.33%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders